{"url_path":"/sec/avln/8-k/2026-07-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1540171/0001193125-26-292834-index.html","accession_number":"0001193125-26-292834","cik":"0001540171","ticker":"AVLN","issuer_name":"Avalyn Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1540171/0001193125-26-292834-index.html","primary_entity_key":"0001540171","primary_entity_name":"Avalyn Pharma Inc."},"word_count":92,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n10.1\n\n \n\n[First Amendment to Sublease Agreement, by and between the Registrant and CRISPR Therapeutics, Inc., dated June 29, 2026](ck0001540171-ex10_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nAvalyn Pharma Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJuly 1, 2026\n\nBy:\n\n/s/ Lyn Baranowski\n\n \n\n \n\n \n\nLyn Baranowski\nChief Executive Officer\n(Principal Executive Officer)"}